- Email: [email protected]
Correction to Lancet Oncol 2017; 18: e564
Corrections
Correction to Lancet Oncol Correction to Lancet Oncol Correction to Lancet Oncol 2017; 18: 1327–37 2017; 18: 1338–47 2017; 18: e564 Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 2017; 18: 1327–37—In the Results section of this Article, the data presented for any-grade adverse diarrhoea events should read “diarrhoea (168 [36%] vs 185 [41%])”. These corrections have been made to the online version as of Sept 27, 2017, and the printed Article is correct.
www.thelancet.com/oncology Vol 18 October 2017
Platzbecker U, Germing U, Götze KS, et al. Luspatercept for the treatment of anaemia in patients with lowerrisk myelodysplastic syndromes (PACE-MDS): a multicentre, openlabel phase 2 dose-finding study with long-term extension study. Lancet Oncol 2017; 18: 1338–47—In the Acknowledgments, Carlos Lanza should have read Carlo Lanza. This correction has been made to the online version as of Sept 27, 2017, and the printed Article is correct.
Gilbert JA. Pazopanib for advanced liposarcoma. Lancet Oncol 2017; 18: e564—In the second paragraph of Brian Samuels’ affiliation, the sentence in parentheses should have read “(Summit Cancer Centers, Post Falls, ID, USA)”. In the third paragraph, the sentence and quote from Brian Samuels should have read, “As Samuels summarised, ‘We decided to recapitulate the original phase 2 study in liposarcomas… Pazopanib is active in the treatment of liposarcomas, just as it is for other subtypes of sarcoma.’” Finally, the reference cited in the margin should have read, “For the study by van der Graaf and colleagues see Lancet 2012; 379: 1879–86”. These corrections has been made to the online version as of Sept 27, 2017.
e562
Correction to Lancet Oncol Correction to Lancet Oncol Correction to Lancet Oncol 2017; 18: 1327–37 2017; 18: 1338–47 2017; 18: e564 Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 2017; 18: 1327–37—In the Results section of this Article, the data presented for any-grade adverse diarrhoea events should read “diarrhoea (168 [36%] vs 185 [41%])”. These corrections have been made to the online version as of Sept 27, 2017, and the printed Article is correct.
www.thelancet.com/oncology Vol 18 October 2017
Platzbecker U, Germing U, Götze KS, et al. Luspatercept for the treatment of anaemia in patients with lowerrisk myelodysplastic syndromes (PACE-MDS): a multicentre, openlabel phase 2 dose-finding study with long-term extension study. Lancet Oncol 2017; 18: 1338–47—In the Acknowledgments, Carlos Lanza should have read Carlo Lanza. This correction has been made to the online version as of Sept 27, 2017, and the printed Article is correct.
Gilbert JA. Pazopanib for advanced liposarcoma. Lancet Oncol 2017; 18: e564—In the second paragraph of Brian Samuels’ affiliation, the sentence in parentheses should have read “(Summit Cancer Centers, Post Falls, ID, USA)”. In the third paragraph, the sentence and quote from Brian Samuels should have read, “As Samuels summarised, ‘We decided to recapitulate the original phase 2 study in liposarcomas… Pazopanib is active in the treatment of liposarcomas, just as it is for other subtypes of sarcoma.’” Finally, the reference cited in the margin should have read, “For the study by van der Graaf and colleagues see Lancet 2012; 379: 1879–86”. These corrections has been made to the online version as of Sept 27, 2017.
e562